Dynavax Technologies Corp(DVAX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.38 | Insider Own | 0.18% | Shs Outstand | 117.4M | Perf Week | - |
| Market Cap | 1.82B | Forward P/E | - | EPS next Y | - | Insider Trans | -91.25% | Shs Float | 116.5M | Perf Month | -1.15% |
| Enterprise Value | 1.46B | PEG | - | EPS next Q | - | Inst Own | 95.93% | Short Float | 8.4% | Perf Quarter | 39.14% |
| Income | -0.04B | P/S | 5.51 | EPS this Y | - | Inst Trans | - | Short Ratio | 3.12 | Perf Half Y | 47.76% |
| Sales | 0.33B | P/B | 3.41 | EPS next 5Y | - | ROA | -4.32% | Short Interest | 9.79M | Perf YTD | 0.78% |
| Book/sh | 4.55 | P/C | 2.81 | EPS past 3/5Y | -27.72% - | ROE | -7.14% | 52W High | -1.46% ($15.73) | Perf Year | 17.87% |
| Cash/sh | 5.52 | P/FCF | 22.6 | Sales past 3/5Y | -14.08% 51.08% | ROIC | -5.57% | 52W Low | 68.48% ($9.20) | Perf 3Y | 40.91% |
| Dividend Est. | - | EV/EBITDA | 78.23 | EPS Y/Y TTM | -310.39% | Gross Margin | 83.17% | Volatility(W/M) | 0.23% 0.4% | Perf 5Y | 46.23% |
| Dividend TTM | - | EV/Sales | 4.42 | Sales Y/Y TTM | 26.73% | Oper. Margin | 3.16% | ATR (14) | 0.11 | Perf 10Y | -14.88% |
| Dividend Ex-Date | - | Quick Ratio | 6.94 | EPS Q/Q | 81.6% | Profit Margin | -13.13% | RSI (14) | 76 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 7.62 | Sales Q/Q | 17.67% | SMA20 | -0.38% ($15.56) | Beta | 0.93 | Target Price | $16 |
| Payout | - | Debt/Eq | 0.54 | Earnings | 2025/11/5 | SMA50 | 12.55% ($13.77) | Rel Volume | 0 | Prev Close | $15.5 |
| Employees | 405 | LT Debt/Eq | 0.46 | EPS/Sales Surpr. | 66.53% 0.93% | SMA200 | 38.23% ($11.21) | Avg Volume(3M) | 3.14M | Price | $15.5 |
| IPO | 2004/2/19 | Option/Short | Yes/No | Trades | 0 | Volume | - | Change | - |
💉 A biotech company specializing in vaccines. HEPLISAV-B, a hepatitis B vaccine, is experiencing high growth. 2025 revenue is projected between $15M and $325M, with a market share of 45%. Acquired by Sanofi (Q1 2026).
Over the past 1 year, on the higher side
1% below its 1-year high.
Traded less than usual. That is 0% of its average volume.
DVAX keeps an operating profit but posts a net loss
Of every $100 in sales, $3.16 is kept as operating profit.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $551. Peers typically go for $200.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +46.2%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 95.9%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
DFSU Dimensional US Sustainability Core 1 ETF <0.01% It ranks #27 of 84 in the industry
Based on market cap of $2B.
BCRX#25 Biocryst Pharmaceuticals Inc $2B PER - 
XERS#26 Xeris Biopharma Holdings Inc $2B PER - DVAX#27 Dynavax Technologies Corp $2B PER - 
ALVO#27 Alvotech $2B PER - 
ANIP#28 ANI Pharmaceuticals Inc $2B PER 15.7 
FAQ
What kind of company is DVAX?
DVAX belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of DVAX?
The market cap of DVAX is approximately $1.8B, ranking 2,113 within its sector.
What is the 52-week high and low for DVAX?
DVAX has recorded a 52-week high of $15.73 and a low of $9.20.
